Drugs / UMESOLERBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05430919 | Aug 2022 → Jul 2023 | allergic rhinitis, conjunctivitis | Regeneron Pharmaceuticals | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04709575 | Jan → Aug 2021 | allergic rhinitis, conjunctivitis | Regeneron Pharmaceuticals | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UMESOLERBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095374 ↗ |
| Known as | REGN5714 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04709575 ↗ |
| Modality | Monoclonal antibody | “Anti-Bet v 1 Monoclonal Antibodies” NCT05430919 ↗ |
| Route | Subcutaneous | “REGN5713-5714-5715 administered subcutaneously” NCT04709575 ↗ |